Clipboard Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 79)
Clipboard Health logo

Clipboard Health

LeaderHealthcare

General

Healthcare per-diem staffing marketplace with 90%+ shift-fill rate and $100M revenue; profitable since 2022 backed by Sequoia competing with Shiftkey and CareRev for nurse per-diem placement.

AI VisibilityBeta
Overall Score
B79
Category Rank
#28 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
84
Gemini
79

About

Clipboard Health is a healthcare staffing marketplace that connects per-diem nurses, CNAs, and allied health professionals with healthcare facilities (nursing homes, hospitals, urgent care centers) for shift work — achieving a 90%+ shift-fill reliability rate versus the 60% industry average for traditional staffing agencies, and maintaining profitability since 2022. A Y Combinator graduate, Clipboard Health reached $100 million in annual revenue within three years of founding, raised $94.1 million total led by Sequoia Capital, and serves tens of thousands of healthcare professionals across 1,000+ facilities.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

79
Overall Score
93
#28
Category Rank
#1
74
AI Consensus
80
stable
Trend
stable
76
ChatGPT
94
84
Perplexity
89
79
Gemini
94
76
Claude
92
85
Grok
98

Key Details

Category
General
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.